April 18th 2024
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
Racial Disparities in Cardiovascular Events from Rheumatoid Arthritis
February 5th 2016Connective tissue disease (CTD) groups together various disorders, such as rheumatoid arthritis and lupus. A new study from the University of Chicago found that complications from these diseases are more prominent based on race.
Treating the Adolescent Endocrine Patient a Delicate Process
February 3rd 2016Teenagers can be tricky patients to treat. Parents know that, patients who progress through the adolescent years and reflect on their teen years know that, and increasingly, organized medicine is acknowledging it with structured specialties in adolescent medicine. Endocrinologists who treat adolescents need unique communication skills and plenty of patience.
Researchers to Study Biomarkers for Early Detection of Diabetic Kidney Disease
October 24th 2015As part of a multi-institutional effort, researchers in the fields of proteomics, lipidomics, and metabolomics will collaborate to discover more effective ways of predicting which patients with type 1 diabetes are at greater risk for developing kidney disease.
Lipids: Local Anesthetic Systemic Toxicity and Broader Applications
October 22nd 2015Lipid resuscitation therapy was identified in 1998 as an effective treatment for local anesthetic systemic toxicity. Since then, researchers have developed a better understanding of the risk factors involved and the manner in which lipids work, using both dynamic scavenging and direct cardiotonic effects.
PCSK9 Inhibitor Dramatically Reduces Cholesterol in Patients with Familial Hypercholesterolemia
The Sanofi/Regeneron PCSK9 inhibitor alirocumab (Praluent)- approved in July in the US - lowered cholesterol in patients with familial hypercholesterolemia to levels "unreachable with statins" researchers said at the European Society of Cardiology meeting in London, UK.